By Frank Prenesti
Date: Monday 01 Oct 2018
(Sharecast News) - AstraZeneca said it had agreed a $200m deal with Germany's Cheplapharm Arzneimittel for the European commercial rights to Atacand and Atacand Plus heart and hypertension treatments.
Sunday share tips: AstraZeneca, Genus, 'Dogs of ... | 30-Jul-2017 | ShareCast |
AstraZeneca co-develops treatment for Alzheimer'... | 09-Dec-2016 | ShareCast |
No recent information was found.
Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
Currency | UK Pounds |
Share Price | 12,892.00p |
Change Today | 128.92p |
% Change | 0.00 % |
52 Week High | 12,940.00p |
52 Week Low | 9,642.00p |
Volume | 433,811 |
Shares Issued | 1,264.16m |
Market Cap | £162,976m |
Time | Volume / Share Price |
16:29 | 4 @ 12,880.00p |
16:29 | 58 @ 12,880.00p |
16:29 | 71 @ 12,880.00p |
16:29 | 154 @ 12,880.00p |
16:29 | 7 @ 12,880.00p |
You are here: research